欧普特理疗公司的LYTENAVATM获得英国治疗湿性AMD的批准, Outlook Therapeutics' LYTENAVA™ got UK approval for treating wet AMD, offering a new treatment option.

视野治疗公司宣布,苏格兰药物联盟已建议LYTENAVATM用于治疗苏格兰NHS内的湿性老年性黄斑变性 (湿性AMD). Outlook Therapeutics announced that the Scottish Medicines Consortium has recommended LYTENAVA™ for treating wet age-related macular degeneration (wet AMD) within Scotland's NHS. 这标志着英国首个获得许可的贝瓦西祖马布眼科配方用于湿性AMD,市场独家权10年. This marks the first licensed ophthalmic formulation of bevacizumab for wet AMD in the UK, with 10 years of market exclusivity. 该药物现已在联合王国市场上提供,为湿性AMD病人提供了新的治疗选择。 The drug is now commercially available in the UK, offering a new treatment option for patients with wet AMD.